Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin in EBV+ CD30+ Lymphomas
NCT02388490Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Mar 2016
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in lymphoma, sponsored by Seoul National University Hospital. Started Mar 2016; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT02388490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388490.